Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.
Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
